The Oversight Committee is currently holding a hearing to examine the high cost of biotech medicines to our health care system, as well the prospects and need for a pathway that would allow the FDA to approve safe and affordable generic versions of biotech drugs.
Watch Chairman Henry Waxman’s opening remarks:
“Some of these drugs cost each patient tens of thousands of dollars a year, some can cost hundreds of thousands per year. Many people cannot get access to these near-miracles, and even when people can get them, the prices drive up the costs of Medicare, Medicaid, and health insurance overall. Why isn’t the market helping?”